ENDRA Life Sciences Inc. (NDRA)

Over the past six months, ENDRA Life Sciences, Inc.'s stock price experienced a decline. Key events include earnings reports, an Annual General Meeting, and a private investment in public equity (PIPE) financing that helped the company regain Nasdaq compliance. ENDRA launched a strategic initiative to enhance balance sheet flexibility and announced a "Yield-to-Innovation" strategy. Positive results from its TAEUS Liver device feasibility study were announced, and the company reduced operating expenses while strengthening its management team and confirming positive FDA alignment.

A reliable seasonal profile for ENDRA Life Sciences Inc. products and services cannot be definitively established due to limited historical data. Analysis suggests a seasonal timeframe from November 20 to February 9 has historically resulted in a geometric average return above the S&P 500 Total Return Index, but caution is advised due to insufficient data. The seasonal timeframe for NDRA correlates poorly with the broader Healthcare sector's seasonal strength.

ENDRA Life Sciences, Inc. is a medical technology company focused on enhancing clinical diagnostic ultrasound capabilities. Headquartered in Ann Arbor, Michigan, ENDRA operates within the Healthcare sector, specifically in Diagnostics & Research and Medical Specialties. Their primary product is the Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology, which aims to visualize tissue like MRI but at a lower cost. The initial focus is on non-invasive measurement of liver fat to assess steatotic liver disease. ENDRA is also exploring other clinical uses for TAEUS, such as visualizing tissue temperature and vascular imaging.

ENDRA Life Sciences Inc. is based in Ann Arbor, Michigan, United States. Specific details about its international operational or market presence are not extensively detailed in the provided information.

ENDRA Life Sciences' brand reputation has been positively influenced by positive feasibility study results for its TAEUS Liver device, strategic operational improvements, and positive feedback from the FDA. The company also expanded its intellectual property portfolio and regained Nasdaq compliance.

The ownership structure of ENDRA Life Sciences (NDRA) includes institutional, insider, and retail investors. Institutional investors own approximately 1.09% to 2.01% of the stock, insiders own 7.46% to 96.17%, and retail investors and public companies own 0.24% to 90.53%. Major institutional owners include DRW Securities, LLC, FSMAX - Fidelity Extended Market Index Fund, and others. Longboard Capital Advisors LLC and Anthony Digiandomenico are significant individual shareholders.